Keywords : PLC
The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects. This report is built using data and information sourced from Global Industries Direct’s proprietary databases, Morria Biopharmaceuticals Plc’s corporate website, SEC filings, investor presentations and featured press releases, both from Morria Biopharmaceuticals Plc and market -specific th...
More »
Search ReportLinker
The Largest Collection of Market Research Reports
» 1.2 Million Industry Reports
» 450,000 Company Profiles
» 850,000 Market Briefings
» 40,000 Country Guides
From +200,000 authoritative sources
The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.
This report is built using data and information sourced from Global Industries Direct’s proprietary databases, Morria Biopharmaceuticals Plc’s corporate website, SEC filings, investor presentations and featured press releases, both from Morria Biopharmaceuticals Plc and market -specific third party sources, put together by Global Industries Direct’s team.
Scope of the Research
- Morria Biopharmaceuticals Plc - Brief Morria Biopharmaceuticals Plc overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of Morria Biopharmaceuticals Plc human therapeutic division.
- Detailed Analysis of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
- Product profiles for late stage and clinical stage products of Morria Biopharmaceuticals Plc with complete description of the product’s developmental history, mechanism of action, therapeutic class, target and major milestones.
- Recent updates of the Morria Biopharmaceuticals Plc’s pipeline in the last quarter.
- Key discontinued and dormant projects.
- Latest news and deals relating to the products.
Why Should You Get This Report?
- Evaluate Morria Biopharmaceuticals Plc’s strategic position with total access to detailed information on its product pipeline.
- Assess the growth potential of Morria Biopharmaceuticals Plc in its therapy areas of focus.
- Identify new drug targets and therapeutic classes in the Morria Biopharmaceuticals Plc’s Research and Development portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
- Exploit collaboration and partnership opportunities with Morria Biopharmaceuticals Plc.
- Avoid Intellectual Property Rights related issues.
- Explore the dormant and discontinued projects of Morria Biopharmaceuticals Plc and identify potential opportunities in those areas.
Global Electronic Component And Semiconductor Industry
Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Morria Biopharmaceuticals Plc Snapshot 5
Morria Biopharmaceuticals Plc Overview 5
Key Information 5
Key Facts 5
Morria Biopharmaceuticals Plc – Research and Development Overview 6
Key Therapeutic Areas 6
Morria Biopharmaceuticals Plc – Pipeline Review 8
Pipeline Products by Stage of Development 8
Pipeline Products – Monotherapy 9
Morria Biopharmaceuticals Plc – Pipeline Products Glance 10
Morria Biopharmaceuticals Plc Clinical Stage Pipeline Products 10
Phase II Products/Combination Treatment Modalities 10
Morria Biopharmaceuticals Plc – Early Stage Pipeline Products 11
Pre-Clinical Products/Combination Treatment Modalities 11
Morria Biopharmaceuticals Plc – Drug Profiles 12
CFX-1 12
MRX-5 13
MRX4 14
MRX6 15
OPX1 16
Morria Biopharmaceuticals Plc – Pipeline Analysis 17
Morria Biopharmaceuticals Plc – Pipeline Products by Therapeutic Class 17
Morria Biopharmaceuticals Plc - Pipeline Products By Target 18
Morria Biopharmaceuticals Plc – Pipeline Products by Route of Administration 19
Morria Biopharmaceuticals Plc – Recent Pipeline Updates 20
Morria Biopharmaceuticals Plc - Dormant Projects 21
Morria Biopharmaceuticals Plc – Locations And Subsidiaries 22
Head Office 22
Other Locations & Subsidiaries 22
Company's Recent Developments 23
Morria Biopharmaceuticals Plc, Recent Developments 23
July 27, 2005: Morria Biopharmaceuticals Announces Promising Asthma Pre-Clinical Results Of MRX3 For Treatment Of Asthma 23
August 25, 2009: Morria Biopharmaceuticals Plc. Obtains Institutional Review Board Clearance to Conduct Phase II Study in Contact Dermatitis Patients Using MRX6, a November el Topical Anti-Inflammatory Drug 23
June 24, 2008: Morria Biopharmaceuticals Plc Announces The Initiation Of A Phase II Clinical Multi-dose Study Of MRX-4 In Allergic Rhinitis 23
October 23, 2007: Morria Biopharmaceuticals Plc Initiates Phase I Clinical Study Of MRX-4 In Allergic Rhinitis 24
April 21, 2010: Morria Initiates Phase II Study In Contact Dermatitis Patients Using Topical Anti-Inflammatory Drug MRX6 24
January 16, 2008: Morria Biopharmaceuticals Plc Announces Preliminary Safety And Tolerability Results From Its Phase I Clinical Study Of MRX-4 in Allergic Rhinitis Patients 25
June 15, 2010: Morria Announces Positive Safety, Tolerability And Preliminary Efficacy Results For MRX-4 Phase II Study In Allergic Rhinitis 25
February 14, 2007: Morria Biopharmaceuticals Plc. Announces Publication Of The Results Of Its Human Pilot Study In Contact Dermatitis Patients Of MRX1, A November el First-In-Class MFAID. 26
June 11, 2008: Morria Biopharmaceuticals Plc Announces Regulatory Approval To Commence Phase II Clinical Study Of MRX-4 In Allergic Rhinitis 27
June 08, 2006: Morria Biopharmaceuticals Plc announces promising pre-clinical results in Inflammatory Bowel Disease (IBD) 27
November 06, 2008: Biopharmaceuticals Plc Announces Positive Clinical Results for MRX-4 In Its Phase II Clinical Study In Allergic Rhinitis Patients 28
July 03, 2006: Morria Biopharmaceuticals Announces Promising Preclinical Results In Inflammatory Bowel Disease 28
June 03, 2010: Morria To Present Phase II Study Results Of MRX-4 In Allergic Rhinitis Patients At Upcoming EAACI Congress 29
Financial Deals Landscape 30
Morria Biopharmaceuticals Plc, Deals Summary 30
Morria Biopharmaceuticals Plc, Pharmaceuticals & Healthcare, Deal Details 31
Equity Offering 31
Morria Biopharmaceuticals Completes Private Placement Of US$ 3.19 Mln 31
Appendix 33
Methodology 33
Coverage 33
Secondary Research 33
Primary Research 34
Expert Panel Validation 34
Contact Us 34
Disclaimer 34
List of Tables
Morria Biopharmaceuticals Plc, Facts and Figures 5
Morria Biopharmaceuticals Plc, Key Facts 5
Morria Biopharmaceuticals Plc – Pipeline by Therapy Area and Indication, H2 2011 7
Morria Biopharmaceuticals Plc – Pipeline by Stage of Development, H2 2011 8
Morria Biopharmaceuticals Plc – Monotherapy Products in Pipeline, H2 2011 9
Morria Biopharmaceuticals Plc - Phase II, H2 2011 10
Morria Biopharmaceuticals Plc – Pre-Clinical, H2 2011 11
Morria Biopharmaceuticals Plc - Pipeline By Therapeutic Class, H2 2011 17
Morria Biopharmaceuticals Plc - Pipeline By Target, H2 2011 18
Morria Biopharmaceuticals Plc – Pipeline By Route of Administration, H2 2011 19
Morria Biopharmaceuticals Plc – Recent Pipeline Updates, H2 2011 20
Morria Biopharmaceuticals Plc - Dormant Developmental Projects, 2010 21
Morria Biopharmaceuticals Plc, Subsidiaries 22
Morria Biopharmaceuticals Plc, Deals Summary 30
Morria Biopharmaceuticals Completes Private Placement Of US$ 3.19 Mln 31
List of Figures
Morria Biopharmaceuticals Plc – Pipeline by Therapy Area and Indication, H2 2011 7
Morria Biopharmaceuticals Plc – Pipeline by Stage of Development, H2 2011 8
Morria Biopharmaceuticals Plc – Monotherapy Products in Pipeline, H2 2011 9
Morria Biopharmaceuticals Plc – Pipeline By Therapeutic Class, H2 2011 17
Morria Biopharmaceuticals Plc - Pipeline By Target, H2 2011 18
Morria Biopharmaceuticals Plc – Pipeline By Route of Administration, H2 2011 19
